Organisation paid for research Program year 2025 Source: CMS Open Payments

Center for Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$4,145,458

348 payments

Through program year 2025, Center for Clinical Trials LLC is reported as receiving $4,145,458 in research payments, across 348 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $264,761 9
2024 Research $159,569 17
2023 Research $507,722 77
2022 Research $1,665,148 84
2021 Research $886,055 62
2020 Research $504,381 68
2019 Research $157,822 31

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $1,928,197 106 payments
  2. Pfizer Inc. $1,521,005 145 payments
  3. Allergan Inc. $500,131 71 payments
  4. Seqirus USA Inc $72,841 11 payments
  5. AbbVie, Inc. $49,724 9 payments
  6. Teva Pharmaceuticals USA, Inc. $44,539 3 payments
  7. Sanofi Pasteur Inc. $22,276 2 payments
  8. Amarin Pharma Inc. $6,745 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $1,490,739 74 payments
  2. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $929,602 42 payments
  3. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $327,350 23 payments
  4. A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults $242,485 7 payments
  5. Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) $159,362 14 payments
  6. Clinical Trial (LIN-MD-66: PED Longterm safety study) $149,892 13 payments
  7. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. $134,117 10 payments
  8. A Phase 2 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine Given With Or Separately From 13Valent Pneumococcal Conjugate Vaccine in Healthy Infants $129,289 38 payments
  9. A Phase 3 Randomized Activecontrolled Observerblinded Trial to Assess the Safety Tolerability and Immunogenicity of Menabcwy in Healthy Participants 10 to 26 Years of Age $105,195 29 payments
  10. Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) $68,443 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record